Intrinsic value of Contineum Therapeutics, Inc. Class A Common Stock (CTNM)

Live fair value data for Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is currently unavailable. Please check again shortly.

Fallback estimate (fair value API unavailable)

Intrinsic Value (Fair Value): Unlock fair value

Upside: +24.0%

Margin of Safety: +19.4%

Current Price: $256.00

Valuation: Undervalued

Confidence: 6.5/10

Visual Bar

Market Price $256.00Intrinsic Value Locked
Undervalued ✅Fair Value ⚖️Overvalued ❌

This intrinsic value is calculated using 5 different models based on projected revenue growth, profit margins, and a standard discount rate.

Intrinsic Value checker

Enter any ticker to open its intrinsic value analysis page.

Is Contineum Therapeutics, Inc. Class A Common Stock (CTNM) undervalued or overvalued?

Based on the current model output, Contineum Therapeutics, Inc. Class A Common Stock appears to be undervalued with a upside of 24.00%.

Fair value vs market price — Contineum Therapeutics, Inc. Class A Common Stock (CTNM)

Unlock premium access to view the live fair value comparison against current market price for CTNM.

Frequently Asked Questions - CTNM

How is CTNM intrinsic value estimated?

We combine revenue growth, discount rate, and terminal growth assumptions to estimate a fair value range for CTNM.

Is CTNM undervalued or overvalued right now?

CTNM is currently shown as undervalued based on the difference between market price and intrinsic value.

How should I use the confidence score?

The confidence score (0 to 10) indicates model certainty from available inputs. Higher values suggest stronger model consistency, not a guarantee of returns.

Related companies — intrinsic value

Peers for CTNM: open their intrinsic value pages.

Explore Other Stocks